Compare LASR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | AMRX |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | 800 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2018 | 2018 |
| Metric | LASR | AMRX |
|---|---|---|
| Price | $64.73 | $16.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $54.31 | $15.60 |
| AVG Volume (30 Days) | 990.9K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 62.99 | ★ 157.89 |
| EPS | 0.01 | ★ 0.19 |
| Revenue | ★ $191,359,000.00 | N/A |
| Revenue This Year | $10.91 | $4.48 |
| Revenue Next Year | $14.32 | $7.13 |
| P/E Ratio | $6,488.00 | ★ $84.29 |
| Revenue Growth | ★ 38.09 | N/A |
| 52 Week Low | $16.87 | $7.67 |
| 52 Week High | $86.95 | $16.61 |
| Indicator | LASR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.20 | 78.56 |
| Support Level | $63.48 | $12.46 |
| Resistance Level | $71.81 | N/A |
| Average True Range (ATR) | 5.43 | 0.57 |
| MACD | -0.84 | 0.27 |
| Stochastic Oscillator | 24.88 | 90.29 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.